A Study of Ispinesib in Metastatic Breast Cancer
A Phase I/II Non-Randomized, Open-Label, Dose-Finding Study of Ispinesib (SB-715992) Followed By a Fixed-Dose Study in Chemotherapy-Naïve Patients With Metastatic Breast Cancer (MBC).
Sponsor: Cytokinetics
Terminated
Trial stopped for administrative reasons prior to official determination of MTD.
Listed as NCT00607841, this PHASE1 trial focuses on Breast Neoplasms and remains terminated or withdrawn. Sponsored by Cytokinetics, it has been updated 8 times since 2007, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Jun 2019 — Jan 2021 [monthly]
Terminated PHASE1
Phase: PHASE1_PHASE2 → PHASE1
-
May 2019 — Jun 2019 [monthly]
Terminated PHASE1_PHASE2
Status: Completed → Terminated
▶ Show 3 earlier versions
-
Jun 2018 — May 2019 [monthly]
Completed PHASE1_PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1_PHASE2
First recorded
Dec 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cytokinetics
For direct contact, visit the study record on ClinicalTrials.gov .